Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients.

1 , 2 ASCVD in Ontario is estimated to occur in 8.9% of adults (over one million adults), and its prevalence shows an increasing trend over time. 3 ASCVD can be prevented effectively with evidence-based therapies, including therapies to reduce low-density lipoprotein cholesterol (LDL-C), such as statins, ezetimibe, and more recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. 4 , 5 , 6 , 7 Globally, guidelines for lipid management have been revised recently; the new guidelines in Canada have been updated with newer data, and notably, with the introduction of PCSK9 inhibitors as a therapy.

also in 63,971 other papers